{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:04:04Z","timestamp":1773270244327,"version":"3.50.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Integrase strand transfer inhibitors (INSTIs) and NNRTIs are widely used in the treatment of HIV, but the real-world adverse events (AEs) profiles of these drugs remain inadequately characterized. We prioritized AEs reported with INSTIs and NNRTIs using data from the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using FAERS data (from FDA approval to June 2024) for 10 drugs (cabotegravir, dolutegravir, raltegravir, elvitegravir, bictegravir, nevirapine, efavirenz, rilpivirine, doravirine and etravirine), we assessed AE clinical priority using a multi-criteria score. The score evaluated four criteria: clinical relevance, reporting proportion, case fatality rate and signal stability. We calculated reporting odds ratios (RORs) with 95% CIs; signals required the lower limit of 95% CIs of the ROR, ROR025\u200a&amp;gt;\u200a1 after Bonferroni correction across [N] tested AEs per drug. Events related to medication errors or HIV-related conditions were excluded. A case-by-case assessment was conducted to evaluate the confounding factors from co-medications and indications<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found 4487\/6362 (70.5%) were low priority (0\u20132 points) and 1849\/6362 (29.1%) were moderate (3\u20135 points), 2, 8, 6 and 15 marginally high-priority (\u22654.5 points) adverse pregnancy outcomes were identified with dolutegravir, raltegravir, nevirapine, efavirenz, respectively; 26 AEs were high clinical priorities (&amp;gt;5 points). After case-by-case assessment, five noteworthy AEs remained. These included efavirenz-related haemolytic anaemia, etravirine-related hepatic failure, dolutegravir-related foetal death, raltegravir-related drug reaction with eosinophilia and systemic symptoms, and raltegravir-related hepatic failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides a systematic framework for evaluating post-marketing AEs of INSTIs and NNRTIs using a semi-quantitative scoring system. Our findings identified five high-priority AEs that require clinical validation and further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag074","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:30:56Z","timestamp":1771331456000},"source":"Crossref","is-referenced-by-count":0,"title":["Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database"],"prefix":"10.1093","volume":"81","author":[{"given":"Gao-yang","family":"Wang","sequence":"first","affiliation":[{"name":"School of International Business, China Pharmaceutical University , Nanjing, Jiangsu 211198 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Xia","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, CIC-1901 Paris-Est, Assistance Publique - H\u00f4pitaux de Paris, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Pharmacology , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Sarangdhar","sequence":"additional","affiliation":[{"name":"Division of Biomedical Informatics, Cincinnati Children\u2019s Hospital Medical Center , 3333 Burnet Avenue, Cincinnati, OH 45229-3026 ,","place":["USA"]},{"name":"Division of Oncology, Cincinnati Children\u2019s Hospital Medical Center , 3333 Burnet Avenue, Cincinnati, OH 45229-3026 ,","place":["USA"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , 3333 Burnet Avenue, Cincinnati, OH 45229-3026 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9110-9604","authenticated-orcid":false,"given":"Yoshihiro","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University , 1-25-4 Daigakunishi, Gifu-shi, Gifu 501-1196 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-fang","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of International Business, China Pharmaceutical University , Nanjing, Jiangsu 211198 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026031103471632600_dkag074-B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study","volume":"43","author":"Palella","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031103471632600_dkag074-B2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/1471-2334-12-296","article-title":"Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study","volume":"12","author":"Prosperi","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2026031103471632600_dkag074-B3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/bcp.12474","article-title":"Adverse drug reactions\u2014examples of detection of rare events using databases","volume":"80","author":"Chan","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2026031103471632600_dkag074-B4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"key":"2026031103471632600_dkag074-B5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/bjd.19504","article-title":"The value of case reports in pharmacovigilance","volume":"183","author":"Garcia-Doval","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026031103471632600_dkag074-B6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf"},{"key":"2026031103471632600_dkag074-B7","doi-asserted-by":"publisher","first-page":"2023-5-9","DOI":"10.7573\/dic.2023-5-9","article-title":"META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports","volume":"12","author":"Murray","year":"2023","journal-title":"Drugs Context"},{"key":"2026031103471632600_dkag074-B8","doi-asserted-by":"publisher","first-page":"e1247","DOI":"10.1002\/prp2.1247","article-title":"Integrase inhibitor drugs during pregnancy and congenital anomalies: a case\/non-case study from the global pharmacovigilance database VigiBase\u00ae","volume":"12","author":"Saint-Lary","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"2026031103471632600_dkag074-B9","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/jac\/dkad187","article-title":"Association of depression and suicidal behaviour reporting with HIV integrase inhibitors: a global pharmacovigilance study","volume":"78","author":"Pr\u00e9ta","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026031103471632600_dkag074-B10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bcp.15075","article-title":"In utero exposure to antiretroviral drugs and pregnancy outcomes: analysis of the French ANRS pharmacovigilance database","volume":"88","author":"Saint-Lary","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026031103471632600_dkag074-B11","doi-asserted-by":"publisher","first-page":"eabn2110","DOI":"10.1126\/scitranslmed.abn2110","article-title":"A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis","volume":"15","author":"Tsai","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026031103471632600_dkag074-B12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2026031103471632600_dkag074-B13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2026031103471632600_dkag074-B14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.08.010","article-title":"Pharmacovigilance studies without a priori hypothesis: systematic review highlights inappropriate multiple testing correction procedures","volume":"162","author":"Gaucher","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"2026031103471632600_dkag074-B15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol"},{"key":"2026031103471632600_dkag074-B16","author":"Centers for Disease Control and Prevention"},{"key":"2026031103471632600_dkag074-B17","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"2026031103471632600_dkag074-B18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031103471632600_dkag074-B19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40264-023-01391-4","article-title":"Enhancing transparency in defining studied drugs: the open-source living DiAna dictionary for standardizing drug names in the FAERS","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2026031103471632600_dkag074-B20","doi-asserted-by":"publisher","author":"Fusaroli","DOI":"10.17605\/OSF.IO\/ZQU89"},{"key":"2026031103471632600_dkag074-B21","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/01.aids.0000226970.04504.a8","article-title":"Haemolytic anaemia associated with efavirenz","volume":"20","author":"Freercks","year":"2006","journal-title":"AIDS"},{"key":"2026031103471632600_dkag074-B22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/QAD.0000000000002425","article-title":"Drug-induced immune hemolytic anemia because of efavirenz: a case report","volume":"34","author":"Lin","year":"2020","journal-title":"AIDS"},{"key":"2026031103471632600_dkag074-B23","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1159\/000438602","article-title":"Efavirenz induced suicidal death of human erythrocytes","volume":"37","author":"Bissinger","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"2026031103471632600_dkag074-B24","first-page":"386","article-title":"High incidence of zidovudine induced anaemia in HIV infected patients in eastern India","volume":"132","author":"Agarwal","year":"2010","journal-title":"Indian J Med Res"},{"key":"2026031103471632600_dkag074-B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13223-018-0236-y","article-title":"Tuberculosis induced autoimmune haemolytic anaemia: a systematic review to find out common clinical presentations, investigation findings and the treatment options","volume":"14","author":"Rathish","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2026031103471632600_dkag074-B26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/QAD.0000000000000139","article-title":"Abacavir-induced liver toxicity in an HIV-infected patient","volume":"28","author":"Di Filippo","year":"2014","journal-title":"AIDS"},{"key":"2026031103471632600_dkag074-B27","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.S2-005","article-title":"Etravirine induced severe hypersensitivity reaction and fulminant hepatitis: a case report and review of the literature","volume":"S2","author":"Nabha","year":"2012","journal-title":"J AIDS Clin Res"},{"key":"2026031103471632600_dkag074-B28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.12865\/CHSJ.50.02.03","article-title":"Liver damage during treatment with reverse-transcriptase inhibitors in HIV patients","volume":"50","author":"Lungu","year":"2024","journal-title":"Curr Health Sci J"},{"key":"2026031103471632600_dkag074-B29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/QAI.0000000000002035","article-title":"Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir","volume":"81","author":"Vannappagari","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031103471632600_dkag074-B30","doi-asserted-by":"publisher","first-page":"103167","DOI":"10.1016\/j.ebiom.2020.103167","article-title":"Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels","volume":"63","author":"Mohan","year":"2021","journal-title":"EBioMedicine"},{"key":"2026031103471632600_dkag074-B31","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz684","article-title":"Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy","volume":"70","author":"van De Ven","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026031103471632600_dkag074-B32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/12034754231220931","article-title":"Medication associations with severe cutaneous adverse reactions: a case\/non-case analysis using the FDA adverse event reporting system","volume":"28","author":"Godfrey","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"2026031103471632600_dkag074-B33","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/cix096","article-title":"Association of the HLA-B* 53: 01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir","volume":"64","author":"Thomas","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026031103471632600_dkag074-B34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/jac\/dkp446","article-title":"Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C","volume":"65","author":"Vispo","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026031103471632600_dkag074-B35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/QAD.0b013e32835e0752","article-title":"Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis","volume":"27","author":"Ford","year":"2013","journal-title":"AIDS"},{"key":"2026031103471632600_dkag074-B36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/QAI.0000000000000932","article-title":"Critical review: review of the efficacy, safety, and pharmacokinetics of raltegravir in pregnancy","volume":"72","author":"Maliakkal","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031103471632600_dkag074-B37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/QAI.0000000000002031","article-title":"Evaluation of neural tube defects (NTDs) after exposure to raltegravir during pregnancy","volume":"81","author":"Shamsuddin","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031103471632600_dkag074-B38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/QAI.0000000000001924","article-title":"Brief report: surveillance of congenital anomalies after exposure to raltegravir or elvitegravir during pregnancy in the United Kingdom and Ireland, 2008\u20132018","volume":"80","author":"Rasi","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031103471632600_dkag074-B39","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/infdis\/jiaf362","article-title":"Fetal defects in mice treated with integrase strand transfer inhibitors: comparison of dolutegravir, raltegravir, bictegravir, and cabotegravir","volume":"232","author":"Mohan","year":"2025","journal-title":"J Infect Dis"},{"key":"2026031103471632600_dkag074-B40","doi-asserted-by":"publisher","first-page":"1564127","DOI":"10.3389\/fphar.2025.1564127","article-title":"Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology","volume":"16","author":"Xie","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026031103471632600_dkag074-B41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/phar.2242","article-title":"Lack of a clinically significant pharmacokinetic interaction between etravirine and raltegravir using an original approach based on drug metabolism, protein binding, and penetration in seminal fluid: a pharmacokinetic substudy of the ANRS-163 ETRAL study","volume":"39","author":"L\u00ea","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2026031103471632600_dkag074-B42","doi-asserted-by":"publisher","first-page":"e5071","DOI":"10.7759\/cureus.5071","article-title":"Trimethoprim-sulfamethoxazole induced pancytopenia: a common occurrence but a rare diagnosis","volume":"11","author":"Parajuli","year":"2019","journal-title":"Cureus"},{"key":"2026031103471632600_dkag074-B43","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/jcm8091351","article-title":"State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies","volume":"8","author":"Andr\u00e8s","year":"2019","journal-title":"J Clin Med"},{"key":"2026031103471632600_dkag074-B44","doi-asserted-by":"publisher","first-page":"e0285541","DOI":"10.1371\/journal.pone.0285541","article-title":"Trimethoprim-sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: a cohort study","volume":"18","author":"Jacobo-Vargas","year":"2023","journal-title":"PLoS One"},{"key":"2026031103471632600_dkag074-B45","doi-asserted-by":"publisher","first-page":"102832","DOI":"10.1016\/j.jiph.2025.102832","article-title":"Characterizing pancytopenia in a large Asian cohort of people living with HIV: a 23-year nested case-control study","volume":"18","author":"Shen","year":"2025","journal-title":"J Infect Public Health"},{"key":"2026031103471632600_dkag074-B46","doi-asserted-by":"publisher","first-page":"103938","DOI":"10.1016\/j.drudis.2024.103938","article-title":"Generation of a drug-induced renal injury list to facilitate the development of new approach methodologies for nephrotoxicity","volume":"29","author":"Connor","year":"2024","journal-title":"Drug Discov Today"},{"key":"2026031103471632600_dkag074-B47","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/08830185.2014.893301","article-title":"Neutropenia during HIV infection: adverse consequences and remedies","volume":"33","author":"Shi","year":"2014","journal-title":"Int Rev Immunol"},{"key":"2026031103471632600_dkag074-B48","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1097\/QAI.0000000000002038","article-title":"Risk and predictors of esophageal and stomach cancers in HIV-infected veterans: a matched cohort study","volume":"81","author":"Thrift","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031103471632600_dkag074-B49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.24875\/AIDSRev.23000018","article-title":"HIV infection and esophageal cancer in sub-Saharan Africa: a comprehensive meta-analysis","volume":"26","author":"Kamsu-Tchuente","year":"2024","journal-title":"AIDS Rev"},{"key":"2026031103471632600_dkag074-B50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/eci.12427","article-title":"HIV-associated pulmonary arterial hypertension: from bedside to the future","volume":"45","author":"Correale","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"2026031103471632600_dkag074-B51","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/IDR.S152090","article-title":"Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project","volume":"11","author":"Bagella","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2026031103471632600_dkag074-B52","doi-asserted-by":"publisher","first-page":"ofae282","DOI":"10.1093\/ofid\/ofae282","article-title":"Cabotegravir+rilpivirine long-acting: overview of injection guidance, injection site reactions, and best practices for intramuscular injection administration","volume":"11","author":"Teichner","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026031103471632600_dkag074-B53","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/4\/dkag074\/67296728\/dkag074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/4\/dkag074\/67296728\/dkag074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:47:24Z","timestamp":1773215244000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag074\/8513780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag074","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,4]]},"article-number":"dkag074"}}